Nội dung được dịch bởi AI, chỉ mang tính chất tham khảo
Hiệu quả và độ an toàn của curcumin và sự kết hợp của nó với axit boswellic trong viêm khớp thoái hóa: một nghiên cứu so sánh, ngẫu nhiên, đôi mù, đối chứng giả dược
Tóm tắt
Mục tiêu của thử nghiệm lâm sàng này là đánh giá tính hiệu quả và độ an toàn của chiết xuất phức hợp curcuminoid từ thân rễ nghệ cùng với tinh dầu nghệ (CuraMed®) và sự kết hợp của nó với chiết xuất axit boswellic từ rễ nhựa thơm Ấn Độ (Curamin®) so với giả dược trong điều trị bệnh nhân từ 40 đến 70 tuổi mắc viêm khớp thoái hóa (OA). Các hiệu ứng của các viên nang CuraMed® 500 mg (333 mg curcuminoids) và viên nang Curamin® 500 mg (350 mg curcuminoids và 150 mg axit boswellic) được dùng bằng miệng ba lần một ngày trong 12 tuần ở 201 bệnh nhân đã được khảo sát trong một thử nghiệm ngẫu nhiên, đôi mù, đối chứng giả dược theo nhóm song song. Các chỉ số hiệu quả kết quả chính bao gồm các bài kiểm tra chức năng thể chất OA, chỉ số WOMAC được khuyến nghị về đau khớp, cứng khớp buổi sáng, hạn chế chức năng thể chất và sự đánh giá toàn cầu của bệnh nhân về mức độ nghiêm trọng của bệnh. Các hiệu ứng tích cực của cả hai chế phẩm so với giả dược được quan sát sau chỉ 3 tháng điều trị liên tục. Một hiệu ứng đáng kể của Curamin® so với giả dược được quan sát cả trong các bài kiểm tra hiệu suất thể chất và chỉ số đau khớp WOMAC, trong khi hiệu quả vượt trội của CuraMed so với giả dược chỉ được quan sát trong các bài kiểm tra hiệu suất thể chất. Kích thước hiệu ứng so với giả dược là tương đương giữa cả hai nhóm điều trị nhưng tốt hơn trong nhóm Curamin®. Các phương pháp điều trị được dung nạp tốt. Việc sử dụng phức hợp curcumin hoặc sự kết hợp của nó với axit boswellic trong 12 tuần làm giảm các triệu chứng liên quan đến đau ở bệnh nhân mắc OA. Curcumin kết hợp với axit boswellic hiệu quả hơn. Sự kết hợp giữa chiết xuất Curcuma longa và Boswellia serrata trong Curamin® nâng cao hiệu quả điều trị OA, có thể do hiệu ứng hợp lực của curcumin và axit boswellic. Thử nghiệm này đã được đăng ký tại cơ sở dữ liệu www.clinicaltrials.gov. Số đăng ký nghiên cứu: NCT02390349.
Từ khóa
#curcumin #axit boswellic #viêm khớp thoái hóa #thử nghiệm lâm sàng #hiệu quả điều trịTài liệu tham khảo
Aggarwal BB, Gupta SC, Sung B. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol. 2013;169:1672–92.
Nakagawa Y, Mukai S, Yamada S, Matsuoka M, Tarumi E, Hashimoto T, Tamura C, Imaizumi A, Nishihira J, Nakamura T. Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study. J Orthop Sci. 2014;19:933–9.
Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, Togni S, Appendino G. Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev. 2010;15:337–44.
Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, Togni S, Appendino G. Product-evaluation registry of Meriva®, a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. Panminerva Med. 2010;52:55–62.
Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res. 2012;26:1719–25.
Asher GN, Spelman K. Clinical utility of curcumin extract. Altern Ther Health Med. 2013;19:20–2.
Henrotin Y, Gharbi M, Dierckxsens Y, Priem F, Marty M, Seidel L, Albert A, Heuse E, Bonnet V, Castermans C. Decrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by treatment with highly bioavailable curcumin during an exploratory clinical trial. BMC Complement Altern Med. 2014;14:159.
Kuptniratsaikul V, Thanakhumtorn S, Chinswangwatanakul P, Wattanamongkonsil L, Thamlikitkul V. Efficacy and safety of Curcuma Domestica extracts in patients with knee osteoarthritis. J Altern Complement Med. 2009;15:891–7.
Kuptniratsaikul V, Dajpratham P, Taechaarpornkul W, Buntragulpoontawee M, Lukkanapichonchut P, Chootip C, Saengsuwan J, Tantayakom K, Laongpech S. Efficacy and safety of curcuma domestica extracts compared with ibuprofen in patients with knee osteoarthritis: a multicenter study. Clin Interv Aging. 2014;9:451–8.
Madhu K, Chanda K, Saji MJ. Safety and efficacy of curcuma longa extract in the treatment of painful knee osteoarthritis: a randomized placebo-controlled trial. Inflammopharmacology. 2013;21:129–36.
Panahi Y, Rahimnia AR, Sharafi M, Alishiri G, Saburi A, Sahebkar A. Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. Phytother Res. 2014;28:1625–31.
Pinsornsak P, Niempoog S. The efficacy of curcuma Longa L. extract as an adjuvant therapy in primary knee osteoarthritis: a randomized control trial. J Med Assoc Thail. 2012;95:S51–8.
Rahimnia AR, Panahi Y, Alishiri G, Sharafi M, Sahebkar A. Impact of supplementation with curcuminoids on systemic inflammation in patients with knee osteoarthritis: findings from a randomized double-blind placebo-controlled trial. Drug Res (Stuttg). 2015;65:521–5.
Chin KY. The spice for joint inflammation: anti-inflammatory role of curcumin in treating osteoarthritis. Drug Des Devel Ther. 2016;10:3029–42.
Grover AK, Samson SE. Benefits of antioxidant supplements for knee osteoarthritis: rationale and reality. Nutr J. 2016;15:1.
Daily JW, Yang M, Park S. Efficacy of turmeric extracts and curcumin for alleviating the symptoms of joint arthritis: a systematic review and meta-analysis of randomized clinical trials. J Med Food. 2016;19:717–29.
Onakpoya IJ, Spencer EA, Perera R, Heneghan CJ. Effectiveness of curcuminoids in the treatment of knee osteoarthritis: a systematic review and meta-analysis of randomized clinical trials. Int J Rheum Dis. 2017;20:420–33.
Mirzaei H, Shakeri A, Rashidi B, Jalili A, Banikazemi Z, Sahebkar A. Phytosomal curcumin: a review of pharmacokinetic, experimental and clinical studies. Biomed Pharmacother. 2017;85:102–12.
Prasad S, Tyagi AK, Aggarwal BB. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res Treat. 2014;46:2–18.
Kurien BT, Singh A, Matsumoto H, Scofield RH. Improving the solubility and pharmacological efficacy of curcumin by heat treatment. Assay Drug Dev Technol. 2007;5:567–76.
Kurien BT, Matsumoto H, Scofield RH. Nutraceutical value of pure curcumin. Pharmacogn Mag. 2017;13(Suppl 1):S161–3.
Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyal S. A pilot cross-over study to evaluate human oral bioavailability of BCM-95 CG (Biocurcumax) a novel bioenhanced preparation of curcumin. Indian J Pharm Sci. 2008:445–9.
Antoni B. 2008. Composition to enhance the bioavailability of curcumin. US 7883728 B2, US 20080226755 A1. http://www.google.com/patents/US788728.
Gopi S. 2016. A novel composition of curcumin with enhanced bioavailability. PCT/IB2014/063960. EP 3035947 A1, US20160151440, WO2015025263A; https://www.google.com/patents/EP3035947A1?cl=en
Rose U.-B, 2014. A pharmaceutical formulation comprising curcumin. Patent. WO 2014063844, DE 102012219219. EP 2908836 A1, US 20150342904; https://www.google.com/patents/US20150342904?cl=en; https://www.google.com/patents/WO2014063844A1?cl=en; https://www.google.com/patents/DE102012219219A1?cl=en.
Kar SK,Akhtar F, Ray G, Pandey AK, 2010. Curcumin nanoparticles and methods of producing the same WO 2010013224 A2, https://www.google.se/patents/WO2010013224A2?cl=en&dq=curcumin+bioavailability+nanoparticles&hl=en&sa=X&ved=0ahUKEwi09J7Z34vXAhVKb1AKHd6zCXUQ6AEIKDAA.
Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64:353–6.
Hani U, Shivakumar HG. Solubility enhancement and delivery systems of curcumin a herbal medicine: a review. Curr Drug Deliv. 2014;11:792–804.
Giori A, Franceschi F. 2009. Phospholipid complexes of curcumin having improved bioavailability PCT/EP2007/001487; US 20090131373 A1; https://www.google.se/patents/US20090131373?dq=cuccumin+bioavalability&hl=en&sa=X&ved=0ahUKEwjEpLyy24vXAhUBU1AKHfdED34Q6AEIPTAD.
Liju VB, Jeena K, Kuttan R. An evaluation of antioxidant, anti-inflammatory, and antinociceptive activities of essential oil from Curcuma Longa. L Indian J Pharmacol. 2011;43:526–31.
Barrett ML. Proprietary botanical ingredient. Scientific and clinical monograph for BCM-95® Curcumin. American Botanical Council. 1–23. www.herbalgram.org (2016) Accessed 20 Apr 2017.
Antony B, Kizhakedath R, Benny M, Kuruvilla BT. Clinical evaluation of herbal formulation, RHULIEF™, in the management of knee osteoarthritis. Osteoarthritis and Cartilage 2011;19S1:S145.
Kizhakkedath R, Antony B, Benny M, Kuruvilla BT. Clinical evaluation of an herbal formulation, Rhulief®, in the management of knee osteoarthritis. Osteoarthr Cartil. 2013;19(Suppl 1):S145–6.
Kizhakkedath R. Clinical evaluation of a formulation containing Curcuma Longa and Boswellia Serrata extracts in the management of knee osteoarthritis. Mol Med Rep. 2013;8:1542–8.
Ammon HP. Boswellic acids in chronic inflammatory diseases. Planta Med. 2006;72:1100–16.
Ammon HP. Modulation of the immune system by Boswellia Serrata extracts and boswellic acids. Phytomedicine. 2010;17:862–7.
Abdel-Tawab M, Werz O, Schubert-Zsilavecz M. Boswellia Serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clin Pharmacokinet. 2011;50:349–69.
Etzel R. Special extract of BOSWELLIA Serrata (H 15) in the treatment of rheumatoid arthritis. Phytomedicine. 1996;3:91–4.
Gupta PK, Samarakoon SM, Chandola HM, Ravishankar B. Clinical evaluation of Boswellia Serrata (Shallaki) resin in the management of Sandhivata (osteoarthritis). Ayu. 2011;32:478–82.
Cameron M, Chrubasik S. Oral herbal therapies for treating osteoarthritis. Cochrane Database Syst Rev. 2014;5:CD002947.
Kimmatkar N, Thawani V, Hingorani L, Khiyani R. Efficacy and tolerability of Boswellia Serrata extract in treatment of osteoarthritis of knee--a randomized double blind placebo controlled trial. Phytomedicine. 2003;10:3–7.
Sengupta K, Alluri KV, Satish AR, Mishra S, Golakoti T, Sarma KV, Dey D, Raychaudhuri SP. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther. 2008;10:R85.
Sengupta K, Krishnaraju AV, Vishal AA, Mishra A, Trimurtulu G, Sarma KV, Raychaudhuri SK, Raychaudhuri SP. Comparative efficacy and tolerability of 5-Loxin and Aflapin against osteoarthritis of the knee: a double blind,randomized, placebo controlled clinical study. Int J Med Sci. 2010;7:366–77.
Vishal AA, Mishra A, Raychaudhuri SP. A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of aflapin in subjects with osteoarthritis of knee. Int J Med Sci. 2011;8:615–22.
Chrubasik JE, Roufogalis BD, Chrubasik S. Evidence of effectiveness of herbal antiinflammatory drugs in the treatment of painful osteoarthritis and chronic low back pain. Phytother Res. 2007;21:675–83.
Ernst E. Frankincense: systematic review. BMJ. 2008;337:a 2813.
Efferth T, Koch E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr Drug Targets. 2011;12:122–32.
Panossian A, Seo EJ, Wikman G, Efferth T. Synergy assessment of fixed combinations of Herba Andrographidis and radix Eleutherococci extracts by transcriptome-wide microarray profiling. Phytomedicine. 2015;22:981–92.
Comblain F, Sanchez C, Lesponne I, Balligand M, Serisier S, Henrotin Y. Curcuminoids extract, hydrolyzed collagen and green tea extract synergically inhibit inflammatory and catabolic mediator's synthesis by normal bovine and osteoarthritic human chondrocytes in monolayer. PLoS One. 2015;10:e0121654.
Chopra A, Lavin P, Patwardhan B, Chitre D. A 32-week randomized, placebo-controlled clinical evaluation of RA-11, an Ayurvedic drug, on osteoarthritis of the knees. J Clin Rheumatol. 2004;10:236–45.
Chopra A, Saluja M, Tillu G, Sarmukkaddam S, Venugopalan A, Narsimulu G, Handa R, Sumantran V, Raut A, Bichile L, Joshi K, Patwardhan B. Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double-blind, controlled equivalence drug trial. Rheumatology (Oxford). 2013;52:1408–17.
Kulkarni RR, Patki PS, Jog VP, Gandage SG, Patwardhan B. Treatment of osteoarthritis with a herbomineral formulation: a double-blind, placebo-controlled, cross-over study. J Ethnopharmacol. 1991;33:91–5.
Kellgren JH, Lawrence JS. Radiographic assessment of osteoarththritis. AnnRheumDis. 1957;16:494–501.
Bennell K, Dobson F, Hinman R. Measures of physical performance assessments: self-paced walk test (SPWT), stair climb test (SCT), six-minute walk test (6MWT), chair stand test (CST), timed up & go (TUG), sock test, lift and carry test(LCT), and car task. Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S350–70.
Dobson F, Hinman RS, Roos EM, Abbott JH, Stratford P, Davis AM, Buchbinder R, Snyder-Mackler L, Henrotin Y, Thumboo J, Hansen P. Bennell KLOARSI recommended performance-based tests to assess physical function in people diagnosed with hip or knee osteoarthritis. Osteoarthr Cartil. 2013;21:1042–52.
Salaffi F, Leardini G, Canesi B, Mannoni A, Fioravanti A, Caporali R, Lapadula G. Punzi L; GOnorthrosis and quality of life assessment (GOQOLA). Reliability and validity of the western Ontario and McMaster universities (WOMAC) osteoarthritis index in Italian patients with osteoarthritis of the knee. Osteoarthr Cartil. 2003;11:551–60.
Sahebkar A. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res. 2014;28:633–42.
Keenan RT, Swearingen CJ, Yazici Y. Erythrocyte sedimentation rate and C-reactive protein levels are poorly correlated with clinical measures of disease activity in rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis patients. Clin Exp Rheumatol. 2008;26:814–9.
Mobasheri A, Henrotin Y, Biesalski HK, Shakibaei M. Scientific evidence and rationale for the development of curcumin and resveratrol as nutraceutricals for joint health. Int J Mol Sci. 2012;13:4202–32.
Henrotin Y, Lambert C, Couchourel D, Ripoll C, Chiotelli E. Nutraceuticals: do they represent a new era in the management of osteoarthritis? - a narrative review from the lessons taken with five products. Osteoarthr Cartil. 2011;19:1–21.
Henrotin Y, Priem F, Mobasheri A. Curcumin: a new paradigm and therapeutic opportunity for the treatment of osteoarthritis: curcumin for osteoarthritis management. Spring. 2013;2:56. Epub 2013 Feb 18
Olsen NJ. Nutraceuticals for the treatment of osteoarthritis. Minerva Med. 2011;102:33–40.
Shakibaei M, John T, Schulze-Tanzil G, Lehman I, Mobasheri A. Suppression of NF-kappa-B activation by curcumin leads to inhibition of expression of cyclooxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: Implication for the treatment of osteoarthritis. Biochem Pharmacol. 2007;73:1434–45.
Colitti M, Gaspardo B, Della Pria A, Scaini C, Stefanon B. Transcriptome modification of white blood cells after dietary administration of curcumin and non-steroidal anti-inflammatory drug in osteoarthritic affected dogs. Vet Immunol Immunopathol. 2012;147:136–46.
Shen CL, Smith BJ, Lo DF, Chyu MC, Dunn DM, Chen CH, Kwun IS. Dietary polyphenols and mechanisms of osteoarthritis. J Nutr Biochem. 2012;23:1367–77.
Henrotin Y, Clutterbuck AL, Allaway D, Lodwig EM, Harris P, Mathy-Hartert M, Shakibaei M, Mobasheri A. Biological actions of curcumin on articular chondrocytes. Osteoarthr Cartil. 2010;18:141–9.
Mathy-Hartert M, Jacquemond-Collet I, Priem F, Sanchez C, Lambert C, Henrotin Y. Curcumin inhibits pro-inflammatory mediators and metalloproteinase-3 production by chondrocytes. Inflamm Res. 2009;58:899–908.
Sengupta K, Kolla JN, Krishnaraju AV, Yalamanchili N, Rao CV, Golakoti T, Raychaudhuri S, Raychaudhuri SP. Cellular and molecular mechanisms of anti-inflammatory effect of Aflapin: a novel Boswellia Serrata extract. Mol Cell Biochem. 2011;354:189–97.
Moussaieff A, Mechoulam R. Boswellia resin: from religious ceremonies to medical uses; a review of in-vitro, in-vivo and clinical trials. J Pharm Pharmacol. 2009;61:1281–93.
Takada Y, Ichikawa H, Badmaev V, Aggarwal BB. Acetyl-11-Ketob-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-kB and NF-kB regulated gene expression. J Immunol. 2006;176:3127–40.
Blain EJ, Ali AY, Duance VC. Boswellia Frereana (frankincense) suppresses cytokine-induced matrimetalloproteinase expression and production of pro-inflammatory molecules in articular cartilage. Phytother Res. 2010;24:905–12.
Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomized controlled trials. Ann Rheum Dis. 2008;67:1716–23.
Zou K, Wong J, Abdullah N, Chen X, Smith T, Doherty M, Zhang W. Examination of overall treatment effect and the proportion attributable to contextual effect in osteoarthritis: meta-analysis of randomized controlled trials. Ann Rheum Dis. 2016;75:1964–70.
Sabina EP, Indu H, Rasool M. Efficacy of boswellic acid on lysosomal acid hydrolases, lipid peroxidation and anti-oxidant status in gouty arthritic mice. Asian Pac J Trop Biomed. 2012;2:128–33.
Reddy GK, Dhar SC. Effect of a new non-steroidal anti-inflammatory agent on lysosomal stability in adjuvant induced arthritis. Ital J Biochem. 1987;36:205–17.